Xcell Biosciences
Xcellbio (www.xcellbio.com) is a venture-backed (Viking Global, Casdin, HBM, Dynamk, Labcorp) San Francisco-based cell therapy technology platform company. Xcellbio is developing research, analytical, and GMP manufacturing products to enhance the potency and persistence of cell therapy candidates. Based on a proprietary metabolism-reprogramming technology, the AVATAR platform has been shown to enhance the metabolic fitness of human cells, leading to significant improvements in vivo potency. The AVATAR platform has been adopted by leading biotech, pharma, and academic institutions, and is nearing its 200th installation. The AVATAR family of products targets preclinical, process development, and GMP manufacturing workflows, spanning the entire spectrum of cell therapy development and production. Cell therapy candidates including, CAR-T, gamma-delta T cells, and TIL-based products have been manufactured using the AVATAR platform, demonstrating enhanced transduction, expansion, and unrivaled potency.
